Compare Equinor ASA (EQNR) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Zoetis Inc — how do they compare? Equinor ASA trades at $43.02 (market cap $101.62B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Equinor ASA is far larger — about 3.4× Zoetis Inc's market cap, and Equinor ASA pays the higher dividend (3.63%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Zoetis Inc for 70 Days on average.
| EQNR | ZTS | |
|---|---|---|
Market Cap | $101.62B | $30.20B |
Volume | 4,991,782 | 6,175,327 |
Sector | Energy | Health |
52-Week High | $45.75 | $147.53 |
52-Week Low | $22.41 | $69.09 |
Typical Hold Time | 59 Days | 70 Days |
Enterprise Value | $110.31B | $37.76B |
Dividend Yield | 3.63% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.01, up 3.36% today, with strong technical momentum indicated by bullish moving averages. The stock shows attractive valuation metrics with a P/E of 11.63 and EV/EBITDA of 2.39, while recent earnings beat expectations in two of the last three quarters. The company maintains solid profitability with 21.32% ROE and continues strategic expansion in LNG markets through new supply agreements.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and share buyback program provide catalysts, but execution risks and commodity price sensitivity require careful monitoring.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
